3-Quinolinecarboxylic acid, 7-[(7S)-7-aMino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-, hydrate
3-Quinolinecarboxylic acid, 7-[(7S)-7-aMino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-, hydrate Basic information
- Product Name:
- 3-Quinolinecarboxylic acid, 7-[(7S)-7-aMino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-, hydrate
- Synonyms:
-
- 3-Quinolinecarboxylic acid, 7-[(7S)-7-aMino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-, hydrate
- Sitafloxacin (Monohydrate)
- 3-Quinolinecarboxylic acid, 7-[(7S)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-, hydrate (1:1)
- 7-[(7S)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-3-Quinolinecarboxylic acid hydrate (1:1)
- 7-[(7S)-7-Amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluoro-cyclopropyl]-1,4-dihydro-4-oxo-quinolin-3-carboxylic acid hydrate
- CAS:
- 163253-37-0
- MF:
- C19H20ClF2N3O4
- MW:
- 427.83
- Mol File:
- 163253-37-0.mol
3-Quinolinecarboxylic acid, 7-[(7S)-7-aMino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-, hydrate Usage And Synthesis
Uses
Sitafloxacin (DU6859a) monohydrate is a potent, orally active fluoroquinolone antibiotic. Sitafloxacin monohydrate shows antichlamydial activity and antibacterial activities against a broad range of gram-positive and gram-negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. Sitafloxacin monohydrate can be used for the research of respiratory tract infection and urinary tract infection[1][2].
in vivo
Sitafloxacin (DU6859a; 12.5-100 mg/kg; i.g.; daily for 4 weeks; BALB/c female mice) monohydrate has antibacterial activity. M. ulcerans cells could be isolated from the inoculated footpads and there was no evidence of footpad swelling[2].
| Animal Model: | BALB/c female mice[2] |
| Dosage: | 12.5, 25, 50 and 100 mg/kg |
| Administration: | Oral gavage; daily, for 4 weeks |
| Result: | Inhibits the growth of Mycobacterium ulcerans and the M. ulcerans cells. |
IC 50
Quinolone
References
[1] Okumura R, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104. DOI:10.1093/jac/dkn136
[2] Dhople AM, et al. Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice. J Chemother. 2003 Feb;15(1):47-52. DOI:10.1179/joc.2003.15.1.47
3-Quinolinecarboxylic acid, 7-[(7S)-7-aMino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-, hydrateSupplier
- Tel
- sales@boylechem.com
- Tel
- 025-83697070
- info@chemlin.com.cn
- Tel
- sales@njromanme.com
- Tel
- +86 18721201413
- sales@biopharmaleader.com
- Tel
- 17368696818